Molecular profiling of dilated cardiomyopathy that progresses to heart failure
Michael A. Burke, Stephen Chang, Hiroko Wakimoto, Joshua M. Gorham, David A. Conner, Danos C. Christodoulou, Michael G. Parfenov, Steve R. DePalma, Seda Eminaga, Tetsuo Konno, Jonathan G. Seidman, Christine E. Seidman
Michael A. Burke, Stephen Chang, Hiroko Wakimoto, Joshua M. Gorham, David A. Conner, Danos C. Christodoulou, Michael G. Parfenov, Steve R. DePalma, Seda Eminaga, Tetsuo Konno, Jonathan G. Seidman, Christine E. Seidman
View: Text | PDF
Research Article Cardiology

Molecular profiling of dilated cardiomyopathy that progresses to heart failure

Abstract

Dilated cardiomyopathy (DCM) is defined by progressive functional and structural changes. We performed RNA-seq at different stages of disease to define molecular signaling in the progression from pre-DCM hearts to DCM and overt heart failure (HF) using a genetic model of DCM (phospholamban missense mutation, PLNR9C/+). Pre-DCM hearts were phenotypically normal yet displayed proliferation of nonmyocytes (59% relative increase vs. WT, P = 8 × 10–4) and activation of proinflammatory signaling with notable cardiomyocyte-specific induction of a subset of profibrotic cytokines including TGFβ2 and TGFβ3. These changes progressed through DCM and HF, resulting in substantial fibrosis (17.6% of left ventricle [LV] vs. WT, P = 6 × 10–33). Cardiomyocytes displayed a marked shift in metabolic gene transcription: downregulation of aerobic respiration and subsequent upregulation of glucose utilization, changes coincident with attenuated expression of PPARα and PPARγ coactivators -1α (PGC1α) and -1β, and increased expression of the metabolic regulator T-box transcription factor 15 (Tbx15). Comparing DCM transcriptional profiles with those in hypertrophic cardiomyopathy (HCM) revealed similar and distinct molecular mechanisms. Our data suggest that cardiomyocyte-specific cytokine expression, early fibroblast activation, and the shift in metabolic gene expression are hallmarks of cardiomyopathy progression. Notably, key components of these profibrotic and metabolic networks were disease specific and distinguish DCM from HCM.

Authors

Michael A. Burke, Stephen Chang, Hiroko Wakimoto, Joshua M. Gorham, David A. Conner, Danos C. Christodoulou, Michael G. Parfenov, Steve R. DePalma, Seda Eminaga, Tetsuo Konno, Jonathan G. Seidman, Christine E. Seidman

×

Figure 2

Activation of the cardiac stress response in PLNR9C/+ mice with disease progression.

Options: View larger image (or click on image) Download as PowerPoint
Activation of the cardiac stress response in PLNR9C/+ mice with disease ...
(A) Progressive and marked increase in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) mRNA levels with disease progression in PLNR9C/+ mice (P < 1 × 10–300 vs. WT at all disease stages). (B) Progressive increase in 4-and-a-half LIM domains protein 1 (Fhl1) mRNA levels with disease progression in PLNR9C/+ mice (P < 1× 10–300 vs. WT at all disease stages). (C) Reduction in the ratio of adult (α-MHC/Myh6) to fetal (β-MHC/Myh7) myosin heavy chain gene expression with disease progression in PLNR9C/+ mice. RNA from n = 3 mice was pooled prior to RNA-seq. Bayesian P value corrected for multiple hypothesis testing (10).